Compare Sana Biotechnology Inc (SANA) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Yum! Brands, Inc. — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Yum! Brands, Inc. trades at $144.69 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 46.6× Sana Biotechnology Inc's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Yum! Brands, Inc. for 132 Days on average.
| SANA | YUM | |
|---|---|---|
Market Cap | $836.71M | $39.02B |
Volume | 4,507,444 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $168.16 |
52-Week Low | $2.68 | $135.77 |
Typical Hold Time | 23 Days | 132 Days |
Enterprise Value | $749.96M | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
YUM trades at $144.82, up 3.18% today, with a bullish technical signal despite mixed indicators. Revenue grew to $8.21B in 2025, with net income of $1.56B and a strong net margin of 25.4%. The company recently sold Pizza Hut for $1.5B and announced a $0.75 dividend, reflecting strategic focus on core brands. Analysts maintain a consensus price target of $170.44, with 39% buy ratings.
YUM presents a stable investment with consistent earnings beats and dividend growth, but faces risks from high debt levels and competitive pressures. Upside is supported by analyst targets and operational efficiency, while macroeconomic headwinds and consumer spending trends pose challenges to sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
